文献速递其他结缔组织病

EphB2受体促进系统性硬化症皮肤纤维化

EphB2 Receptor Promotes Dermal Fibrosis in Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2024-05-15

该研究通过人皮肤活检、EphB2敲除及点突变小鼠模型和SSc真皮成纤维细胞体外实验,发现EphB2在SSc皮肤和成纤维细胞中表达上调,EphB2正向信号介导博来霉素和Tsk1/+模型皮肤纤维化,TGF-β经非经典通路上调EphB2,沉默EPHB2可减弱TGF-β诱导的成纤维细胞向肌成纤维细胞分化。

要点

  • EphB2在SSc皮肤组织和体外培养的SSc真皮成纤维细胞中表达上调。
  • EphB2正向信号是博来霉素和Tsk1/+小鼠模型皮肤纤维化的关键介质。
  • TGF-β经非经典TGF-β/母亲抗decapentaplegic信号上调成纤维细胞EphB2。

核心结论

  • 数据表明TGF-β调控EphB2过表达及激酶介导的正向信号参与SSc皮肤纤维化发生,EphB2是潜在的新治疗靶点。

研究设计与样本

  • 评估正常和SSc人皮肤活检中EphB2表达。
  • 将EphB2敲除小鼠置于博来霉素诱导和紧皮(Tsk1/+)遗传性皮肤纤维化小鼠模型。
  • 使用EphB2激酶失活和过度活跃点突变小鼠评估EphB2正向信号在博来霉素诱导真皮纤维化中的作用。
  • 对SSc患者和健康对照真皮成纤维细胞进行体外研究,随后进行成纤维细胞特异性Ephb2缺陷小鼠的体内分析。

主要发现

  • 与健康对照相比,EphB2在SSc皮肤组织和体外培养的SSc真皮成纤维细胞中表达上调。
  • EphB2表达在两种真皮纤维化动物模型中升高。
  • 在小鼠中,EphB2驱动博来霉素和Tsk1/+两种皮肤纤维化模型的真皮纤维化。
  • EphB2正向信号是真皮纤维化的关键介质。
  • TGF-β细胞因子经非经典TGF-β/母亲抗decapentaplegic信号上调真皮成纤维细胞EphB2,沉默人真皮成纤维细胞EPHB2足以减弱TGF-β诱导的成纤维细胞向肌成纤维细胞分化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Erythropoietin-producing hepatocellular (Eph)/Ephrin cell-cell signaling is emerging as a key player in tissue fibrogenesis. The aim of this study was to test the hypothesis that the receptor tyrosine kinase EphB2 mediates dermal fibrosis in systemic sclerosis (SSc). METHODS: We assessed normal and SSc human skin biopsies for EphB2 expression. The in vivo role of EphB2 in skin fibrosis was investigated by subjecting EphB2-knockout mice to both bleomycin-induced and tight skin (Tsk1/+) genetic mouse models of skin fibrosis. EphB2 kinase-dead and overactive point mutant mice were used to evaluate the role of EphB2 forward signaling in bleomycin-induced dermal fibrosis. In vitro studies were performed on dermal fibroblasts from patients with SSc and healthy controls, which was followed by in vivo analysis of fibroblast-specific Ephb2-deficient mice. RESULTS: Expression of EphB2 is up-regulated in SSc skin tissue and explanted SSc dermal fibroblasts compared with healthy controls. EphB2 expression is elevated in two animal models of dermal fibrosis. In mice, EphB2 drives dermal fibrosis in both the bleomycin and the Tsk1/+ models of skin fibrosis. EphB2 forward signaling is a critical mediator of dermal fibrosis. Transforming growth factor-β (TGF-β) cytokines up-regulate EphB2 in dermal fibroblasts via noncanonical TGF-β/mother against decapentaplegic signaling, and silencing EPHB2 in human dermal fibroblasts is sufficient to dampen TGF-β-induced fibroblast-to-myofibroblast differentiation. Moreover, mice with fibroblast-specific deletion of EphB2 showed impaired fibroblast-to-myofibroblast differentiation and reduced skin fibrosis upon bleomycin challenge. CONCLUSION: Our data implicate TGF-β regulation of EphB2 overexpression and kinase-mediated forward signaling in the development of dermal fibrosis in SSc. EphB2 thus represents a potential new therapeutic target for SSc.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Egal ESA, Kamdem SD, Yoshigi M, et al. EphB2 Receptor Promotes Dermal Fibrosis in Systemic Sclerosis. Arthritis Rheumatol. 2024. PMID: 38589317. doi:10.1002/art.42858

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。